Aroa Biosurgery Limited (ARX.XA)
Cboe AU · AUD
A$0.52 (-0.95%) as of
Key statistics
- EPS (TTM)
- -0.0610
- 52-week range
- 0.4800 – 0.8000
- Beta
- 0.86
- Revenue (TTM)
- 103.85M
- Profit margin
- 4.50%
- Volume
- 31.34k
About Aroa Biosurgery Limited
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
- Headquarters
- Auckland, New Zealand
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.